Drug
TACI receptor-IgG Fc fragment fusion protein clinical trials
Also written Atacicept and VT-001.
- studies test it
- 18
- open now
- 2
- in phase 3
- 4
- first study started
- 2006
Keep track of what changes. Save the TACI receptor-IgG Fc fragment fusion protein studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2008 (4)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 4 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2017 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 15
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 18 · Other 0
EMD Serono (11) · Vera Therapeutics, Inc. (5) · Merck KGaA, Darmstadt, Germany (1) · EMD Serono Research & Development Institute, Inc. (1)
Studies
Open first, then newest update. How each study uses TACI receptor-IgG Fc fragment fusion protein is read from its arms, and is right about nine times in ten.
Testing it · 18
- Atacicept in Multiple Glomerular DiseasesRecruitingPhase 2Vera Therapeutics, Inc.NCT06983028Written as Atacicept
- A Rollover Study to Evaluate the Long-Term Safety and Efficacy of AtaciceptEnrolling by invitationPhase 2Vera Therapeutics, Inc.NCT06674577Written as Atacicept 150 mg
- Atacicept in Subjects With IgA NephropathyActive, not recruitingPhase 3Vera Therapeutics, Inc.NCT04716231Written as Atacicept
- Monthly Dosing of Atacicept in IgANActive, not recruitingPhase 2Vera Therapeutics, Inc.NCT07020923Written as Atacicept
- Atacicept in Subjects With Active Lupus Nephritis (COMPASS)WithdrawnPhase 3Vera Therapeutics, Inc.NCT05609812Written as Atacicept
- Efficacy and Safety of Atacicept in IgA NephropathyTerminatedPhase 2EMD Serono Research & Development Institute, Inc.NCT02808429Written as Atacicept 25 mg
- Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)TerminatedPhase 2EMD SeronoNCT02070978Written as Atacicept 75 mg
- Efficacy and Safety of Atacicept in Systemic Lupus ErythematosusCompletedPhase 2EMD SeronoNCT01972568Written as Atacicept 150 mg
- Atacicept in Multiple Sclerosis Extension Study, Phase IITerminatedPhase 2EMD SeronoNCT00853762Written as Atacicept 25 mg
- Atacicept in Combination With Rituximab in Subjects With Rheumatoid Arthritis (August III)CompletedPhase 2Merck KGaA, Darmstadt, GermanyNCT00664521Written as Atacicept
- A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)TerminatedPhase 2EMD SeronoNCT00642902Written as Atacicept
- The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus NephritisTerminatedPhase 2/3EMD SeronoNCT00573157Written as Atacicept
- Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)CompletedPhase 2/3EMD SeronoNCT00624338Written as Atacicept 75 mg
- A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)CompletedPhase 2EMD SeronoNCT00430495Written as Atacicept
- Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)CompletedPhase 2EMD SeronoNCT00595413Written as Atacicept: with loading dose
- Atacicept in Subjects With Optic NeuritisTerminatedPhase 2EMD SeronoNCT00624468Written as Atacicept
- Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate MofetilTerminatedPhase 1EMD SeronoNCT01369628Written as Atacicept
- Atacicept Demonstrating Dose RESponSeWithdrawnPhase 2EMD SeronoNCT01440231Written as Atacicept
Codes
What other systems call TACI receptor-IgG Fc fragment fusion protein · ClinicalTrials.gg INT005189
- MeSH (NLM) C524618TACI receptor-IgG Fc fragment fusion proteinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) K3D9A0ICQ3ATACICEPTConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C524618 | TACI receptor-IgG Fc fragment fusion protein | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | K3D9A0ICQ3 | ATACICEPT | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.